Skip to main content

When your child needs access to NULIBRY, urgency is critical

ForgingBridges | NULIBRY Access and Support is your source for helping your child get NULIBRY—now and as your child grows

At Origin, we strive to provide NULIBRY to children who need it, which is why we created ForgingBridges | NULIBRY. It is a comprehensive set of support programs dedicated to helping children get access to NULIBRY.

  • If you have insurance, we work with your healthcare provider and insurance company to determine your health plan's coverage policy
  • We offer a variety of support programs based on your insurance coverage and affordability challenges
  • ForgingBridges | NULIBRY offers educational resources regarding treatment with NULIBRY

To sign up for ForgingBridges | NULIBRY, download the enrollment form and complete it with your child’s healthcare provider. Your healthcare provider will then submit the form to ForgingBridges | NULIBRY.

Sign up today

Download Enrollment Form
forging bridges access support program logo

ForgingBridges | NULIBRY
Access and Support

For questions or additional info, give us a call. Our support team is ready to help.

Call 1-888-55BRIDGE

Monday-Friday, 8 am-8 pm ET

The support you need starts here.

Learn About Affordability Options >



NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.



Potential for Photosensitivity

NULIBRY can make the patient oversensitive to sunlight. NULIBRY-treated patients or their caregivers are advised to avoid or minimize patient exposure to sunlight and artificial UV light and adopt precautionary measures when exposed to the sun, including wearing protective clothing and sunglasses, and use broad-spectrum sunscreen with high SPF in patients 6 months of age and older. If photosensitivity occurs, caregivers/patients are advised to seek medical attention immediately and consider a dermatological evaluation.


The most common adverse reactions in NULIBRY-treated patients were infusion catheter–related complications (89%), pyrexia (fever) (78%), viral infection (56%), pneumonia (44%), otitis media (ear infection) (44%), vomiting (44%), and cough/sneezing (44%). Adverse reactions for rcPMP-treated patients were similar to the NULIBRY-treated patients.


Please read the FDA-approved NULIBRY Prescribing Information and Instructions for Use and follow the instructions on how to prepare and administer NULIBRY.

NULIBRY has a potential for photosensitivity; see Warnings and Precautions. Seek medical attention immediately if the patient develops a rash or if they notice symptoms of photosensitivity reactions (redness, burning sensation of the skin, blisters).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.